Jamjoom Pharma to maintain growth trajectory, eyes 34.5% profit margin in 2025: CEO

Tarek Youssef Hosny, CEO of Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) expects the company to maintain its growth trajectory and long-term value creation.

“We are tracking well towards our revenue guidance of CAGR of 12–15% achieving a YTD growth of 13%.

As for our EBITDA margin, we upgrade our target range to 34-34.5% from 31.5-33%, supported by the strong P&L performance seen in 2025,” he said, in an interview with Argaam.

Jamjoom Pharma continues to advance its strategic growth agenda through focused expansion in high-value therapeutic areas and strong business development momentum.

Our pipeline now spans 60 products across Ophthalmology, Cardiometabolic, Dermatology, and Consumer Health — with 17 products under SFDA review, 22 ready for submission, and 21 under development, according to the CEO.

“To date, we have signed 13 strategic partnership agreements with leading global partners to licensing and supply medicines in the MENA and the Gulf, spanning generics and biosimilars across our targeted therapeutic areas.

These partnerships further enhance our access to differentiated, high-growth portfolios and position JP for sustained long-term value creation,” said the top executive.

The CEO also highlighted the continued sales momentum across the company’s core markets during 9M 2025, underscoring the strength of its operational execution and strategic focus.

Saudi Arabia remained the company’s primary growth engine, growing by 13.7% YoY to SAR 794.5 million, accounting for about two thirds of its total revenue.

This growth was driven by volumetric growth in institutional sales enabled by efficient supply chain execution.

Additionally, the Gulf region contributed SAR 156.9 million, led by the UAE and Bahrain emerging as strong contributors with 18.8% and 20.9% growth respectively, reflecting resilient demand and market-tailored brand penetration in high-margin segments through improved commercial execution.

Iraq continued its solid trajectory with 15.7% YoY growth, reaching SAR 104.2 million, supported by digital engagement, strong public-private partnerships, and enhanced distribution channels.

In Egypt, revenue reached SAR 59.0 million, up 14% in local currency, but declining 4.3% in constant currency terms, primarily due to a depreciated average exchange rate compared to last year.

Other export markets delivered SAR 81.6 million, increasing 11.1% YoY, driven by Francophone countries and Morocco, according to the CEO.

He highlighted that Jamjoom Pharma’s profit rose to SAR 395.7 million by the end of 9M 2025, compared to SAR 304.9 million for the same period in 2024.

Revenue also grew by 13%, reaching nearly SAR 1.2 billion.

These results reflect the continued momentum built in the first half and highlights the resilience of Jamjoom’s business model in a dynamic operating environment.

The increase in net profit was supported by strategic focus on high-value, high-margin therapeutic segments, improved operating leverage, lower financial charges and certain one-offs relating to provisions and other income, said the CEO.

The CEO also said that the total production across Jamjoom Pharma’s three manufacturing facilities reached 128 million units, at nearly the same level YoY.

“This decline was primarily driven by a reduction in output at the main Jeddah facility, in line with the company’s inventory optimization strategy, focus on production of high-value strategic brands and transferring production to our new facilities,” he added.

Furthermore, the main Jeddah facility produced 100 million units, with a 89.3% capacity utilization, despite a modest decline, production has been strategically shifted from the main site, allowing for a more balanced and efficient utilization across the facilities, Hosny said.

The Egypt facility significantly ramped up production, produced 22 million units, with a 56.3% capacity utilization, reflecting improved asset utilization and its growing role in supporting regional supply and export capabilities.

The new sterile facility in Jeddah continued its scale-up, produced 6 million units, with a 41.9% capacity utilization, He added.

“These figures highlight the scalability of our manufacturing platform and our strategic commitment to building a resilient to further scale production in 9m 2025 to meet growing market demand and support continued portfolio expansion,” said the CEO.

According to Hosny, the company’s anti-diabetic portfolio maintained strong momentum with 38.6% YoY growth, Cardiovascular therapies also grew by 15.0%, jointly highlighting the momentum in the Cardiometabolic (TA) by 20.1%.

“Gastrointestinal and Consumer Health segments delivered 6.6% and 17.5% growth, respectively, fueled by awareness initiatives and an expanded retail footprint. Pain & Inflammation showed stable growth of 8.4%, while CNS portfolio grew by 9.1% YoY, in line with the company’s ongoing portfolio rationalization efforts,” he added.

The top executive also highlighted that these results reinforce the company’s strategic emphasis on high-impact therapeutic categories, supported by new product introductions—6 brands launched in 9M 2025—and cross-functional alignment across commercial, medical, and operations teams.

As for the Jamjoom Algeria project, the CEO said it continues to progress well and remains a cornerstone of our North Africa growth strategy.

He added that the joint venture sustained its positive momentum and delivered a meaningful financial contribution of SAR 9.3 million during the first nine months of 2025, with a long-term vision to bring Jamjoom’s own flagship ophthalmology and dermatology portfolio into local production once the capital investment project completes.

According to Argaam’s data, Jamjoom Pharma posted SAR 395.7 million net profit for 9M 2025, up compared to SAR 304.9 million in the same period a year ago.